 Triazoles
"Triazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D014230
|
| MeSH Number(s) |
D03.383.129.799
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Triazoles".
Below are MeSH descriptors whose meaning is more specific than "Triazoles".
This graph shows the total number of publications written about "Triazoles" by people in this website by year, and whether "Triazoles" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2005 | 0 | 2 | 2 | | 2006 | 4 | 2 | 6 | | 2007 | 6 | 0 | 6 | | 2008 | 2 | 3 | 5 | | 2009 | 1 | 1 | 2 | | 2010 | 2 | 0 | 2 | | 2011 | 5 | 2 | 7 | | 2012 | 0 | 3 | 3 | | 2013 | 10 | 3 | 13 | | 2014 | 7 | 5 | 12 | | 2015 | 5 | 2 | 7 | | 2016 | 5 | 1 | 6 | | 2017 | 4 | 6 | 10 | | 2018 | 3 | 3 | 6 | | 2019 | 2 | 2 | 4 | | 2020 | 0 | 1 | 1 | | 2021 | 3 | 0 | 3 | | 2022 | 1 | 2 | 3 | | 2023 | 0 | 2 | 2 | | 2024 | 2 | 6 | 8 | | 2025 | 1 | 2 | 3 | | 2026 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Triazoles" by people in Profiles.
-
Koethe JR, Lake JE, Kantor A, Smeaton L, Erlandson K, Moran L, Belaunzaran-Zamudio P, Landay A, Campo RE, Debroy P, Bennet JA, O'Halloran J, Han WM, Alli O, Leonard M, Gulick RM. A 48-Week, Randomized Controlled Trial of Doravirine for Individuals With HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391). Clin Infect Dis. 2026 Jul 23; 83(1):e81-e89.
-
Baker JV, Siegel LK, Losso MH, Vasudeva S, Nordwall JA, Harper K, Grund B, Havens JP, Fletcher CV, Fishchuk R, Kobrynska O, Abutidze A, Metchurtchlishvili R, Ginde AA, Aggarwal NR, Poulakou G, Mourad A, Gibbs KW, Saito S, Chayakulkeeree M, Mootsikapun P, Honda H, Mateu L, Gyrina O, Garcia A, Lee DG, Casey JD, Jain MK, Bengtson CD, Hite RD, Hiranburana N, Matthay MA, Arizmendez N, Nguyen HH, Drelick A, Mena Lora AJ, Parnia S, Trautner BW, Portsmouth SD, Shimizu R, Uehara T, Paredes R, Goodman AL, Vock DM, Gelijns AC, Weintrob AC, Bajema KL, Pett SL, Lundgren J, Schechner AJ, Higgs ES, Lane HC, Matthews GV, Self WH, Reilly C. Ensitrelvir for the Treatment of Hospitalized Adults With COVID-19: An International Phase 3 Randomized Placebo-controlled Trial. Clin Infect Dis. 2026 Jul 23; 83(1):59-69.
-
Tanis S, Simon LE, Alexander AK, Horan TS, Carro MLM, Bonnett SJ, Xie A, Ben-Shlomo R, Owens CE, Danko CG, Lujic J, Cohen PE. Meiotic prophase I disruption as a strategy for nonhormonal male contraception using small-molecule inhibitor JQ1. Proc Natl Acad Sci U S A. 2026 Apr 14; 123(15):e2517498123.
-
Kim JS, Kumar V, Liu L, Choi YJ, Senovaityte S, McCollister BD, Wlodarchak N, Orlicky DJ, Rice PJ, Dai S, Wempe MF, Vázquez-Torres A. DksA inhibitors against intracellular and persistent Salmonella are effective in acute models of infection. Sci Adv. 2026 Mar 20; 12(12):eaea6832.
-
Luetkemeyer AF, Chew KW, Lacey S, Hughes MD, Harrison LJ, Daar ES, Eron J, Fletcher CV, Greninger AL, Hessinger D, Li JZ, Mailhot D, Wohl D, Chayakulkeeree M, Mendoza JLA, Elistratova P, Makinde O, Morgan G, Portsmouth S, Uehara T, Smith D, Currier JS. Ensitrelvir for the Treatment of Nonhospitalized Adults with COVID-19: Results from the SCORPIO-HR, Phase 3, Randomized, Double-blind, Placebo-Controlled Trial. Clin Infect Dis. 2025 07 18; 80(6):1235-1244.
-
Green AL, Minard CG, Liu X, Safgren SL, Pinkney K, Harris L, Link G, DeSisto J, Voss S, Nelson MD, Reid JM, Fox E, Weigel BJ, Glade Bender J. Phase I Trial of Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors (ADVL1414): A Children's Oncology Group Phase I Consortium Trial. Clin Cancer Res. 2025 May 01; 31(9):1587-1595.
-
von Itzstein MS, Burns TF, Dowell JE, Horn L, Camidge DR, York SJ, Eaton KD, Kyle K, Fattah F, Liu J, Mu-Mosley H, Gupta A, Nadeem U, Gao A, Zhang S, Gerber DE. Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2025 Feb 17; 31(4):639-648.
-
Bucayu RFT, Boge CLK, Yildirim I, Avilés-Robles M, Vora SB, Berman DM, Sharma TS, Sung L, Castagnola E, Palazzi DL, Danziger-Isakov L, Yin DE, Roilides E, Maron G, Tribble AC, Soler-Palacin P, López-Medina E, Romero J, Belani K, Arrieta AC, Carlesse F, Nolt D, Halasa N, Dulek D, Rajan S, Muller WJ, Ardura MI, Pong A, Gonzalez BE, Salvatore CM, Huppler AR, Aftandilian C, Abzug MJ, Chakrabarti A, Green M, Lutsar I, Knackstedt ED, Johnson SK, Steinbach WJ, Fisher BT, Wattier RL. Transition to Enteral Triazole Antifungal Therapy for Pediatric Invasive Candidiasis: Secondary Analysis of a Multicenter Cohort Study Conducted by the Pediatric Fungal Network. J Pediatric Infect Dis Soc. 2024 Dec 30; 13(12):633-638.
-
Schuetze KB, Stratton MS, Bagchi RA, Hobby ARH, Felisbino MB, Rubino M, Toni LS, Reges C, Cavasin MA, McMahan RH, Alexanian M, Vagnozzi RJ, McKinsey TA. BRD4 inhibition rewires cardiac macrophages toward a protective phenotype marked by low MHC class II expression. Am J Physiol Heart Circ Physiol. 2025 02 01; 328(2):H294-H309.
-
Srivastava SK, Watkins TR, Nguyen QD, Sharma S, Scales DK, Dacey MS, Shah RE, Chu DS, Grewal DS, Faia LJ, Suhler EB, Genovese MC, Guo Y, Barchuk WT, Besuyen R, Dick AD, Rosenbaum JT. Filgotinib in Active Noninfectious Uveitis: The HUMBOLDT Randomized Clinical Trial. JAMA Ophthalmol. 2024 Sep 01; 142(9):789-797.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|